Hansoh Pharma (03692.HK) announced that on November 1st, the group's self-developed B7-H3 targeted antibody-drug conjugate injection HS-20093 has been approved by the National Drug Administration for inclusion as a breakthrough therapeutic drug, with the indication planned for extensive-stage small cell lung cancer progressing after standard first-line treatment.
翰森製藥(03692.HK)HS-20093納入突破性治療藥物
hansoh pharma (03692.HK) HS-20093 included in breakthrough therapeutic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated